Several pharmaceutical companies are currently developing bi-layer tablets.
For a variety of reasons: patent extension, therapeutic, marketing to name a
few. To reduce capital investment, quite often existing but modified tablet
presses are used to develop and produce such tablets.
GEA Courtoy explains why the development and production of quality bi-layer
tablets needs to be carried out on purpose-built tablet presses to overcome
common bi-layer problems, such as layer-separation, insufficient hardness,
inaccurate individual layer weight control, cross-contamination between the
layers, reduced yield, etc.
Using a modified tablet press may therefore not be your best approach to
producing a quality bi-layer tablet under GMP-conditions. Especially when in
addition high production output is required. Bi-layer tablets: quality and
GMP-requirements.
To produce a quality bi-layer tablet, in a validated and GMP-way, it is
important that the selected press is capable of:
- Preventing capping and separation of the two individual layers that
constitute the bi-layer tablet
- Providing sufficient tablet hardness
- Preventing cross-contamination between the two layers
- Producing a clear visual separation between the two layers
- High yield
- Accurate and individual weight control of the two layers
To read the complete story, click on this link or contact:
Business Contact:
Michael Van den Bossche
Sales Manager
GEA Courtoy nv
BE-1500, Halle, Belgium
Office: +32 2 363
83 19, Mobile: +32 499 98 24 89
Email: michael.vandenbossche@geagroup.
com
Press Contact:
Kris De Baere
Marketing Manager
GEA
Pharma Systems
Office: +32 (0) 3 350 12 41, Mobile: + 32 (0) 473 73 19
45
Email: kris.debaere@geagroup.com